Relmada Therapeutics, Inc. (RLMD)
2.925
-0.18
(-5.95%)
USD |
NASDAQ |
Nov 20, 10:35
Relmada Therapeutics Cash from Operations (Quarterly) : -12.59M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -12.59M |
| June 30, 2026 | -9.606M |
| March 31, 2026 | -15.07M |
| December 31, 2025 | -14.60M |
| September 30, 2025 | -6.722M |
| June 30, 2025 | -6.402M |
| March 31, 2025 | -18.07M |
| December 31, 2024 | -8.800M |
| September 30, 2024 | -16.66M |
| June 30, 2024 | -13.26M |
| March 31, 2024 | -13.04M |
| December 31, 2023 | -10.25M |
| September 30, 2023 | -11.63M |
| June 30, 2023 | -13.27M |
| March 31, 2023 | -16.51M |
| December 31, 2022 | -35.88M |
| September 30, 2022 | -26.86M |
| June 30, 2022 | -21.63M |
| March 31, 2022 | -19.43M |
| December 31, 2021 | -37.66M |
| September 30, 2021 | -20.92M |
| June 30, 2021 | -17.21M |
| March 31, 2021 | -16.09M |
| December 31, 2020 | -6.929M |
| September 30, 2020 | -12.50M |
| Date | Value |
|---|---|
| June 30, 2020 | -4.954M |
| March 31, 2020 | -3.425M |
| June 30, 2019 | -3.667M |
| March 31, 2019 | -2.012M |
| December 31, 2018 | -3.148M |
| September 30, 2018 | -1.671M |
| June 30, 2018 | -2.266M |
| March 31, 2018 | -1.625M |
| December 31, 2017 | -1.132M |
| September 30, 2017 | -0.979M |
| June 30, 2017 | -1.016M |
| March 31, 2017 | -1.855M |
| December 31, 2016 | -1.450M |
| September 30, 2016 | -2.144M |
| June 30, 2016 | -2.826M |
| March 31, 2016 | -3.627M |
| December 31, 2015 | -3.475M |
| September 30, 2015 | -3.216M |
| June 30, 2015 | -4.489M |
| March 31, 2015 | -4.432M |
| December 31, 2014 | -4.984M |
| September 30, 2014 | -2.322M |
| August 31, 2014 | |
| May 31, 2014 | |
| February 28, 2014 | 0.396M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Talphera, Inc. | -3.034M |
| Journey Medical Corp. | -3.437M |
| ANI Pharmaceuticals, Inc. | 83.79M |
| Corcept Therapeutics, Inc. | 142.89M |
| Veru, Inc. | -5.467M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 6.954M |
| Cash from Financing (Quarterly) | 0.0177M |
| Free Cash Flow | -51.86M |
| Free Cash Flow Per Share (Quarterly) | -0.1119 |
| Free Cash Flow to Equity (Quarterly) | -12.59M |
| Free Cash Flow to Firm (Quarterly) | -12.59M |
| Free Cash Flow Yield | -16.62% |